With three times more deaths in the treatment group over placebo in their latest phase 3 trial, ESPR has taken a serious hit in value. This trial is one of many where Esperion is putting their LDL-c lowering drug, Bempedoic Acid (BA), to the test. Their data indicates that BA lowers LDL-c approximately 25% from […]